Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Effectiveness of IV CR845 in Hemodialysis Patients
NCT03998163Phase 3Completed
- Sponsor
- Cara Therapeutics, Inc.
- Start
- May 2019
- Primary completion
- Feb 2020
- Modality
- Peptides, Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of difelikefalin in uremic pruritus, sponsored by Cara Therapeutics, Inc. Primary endpoint: Number of Participants With Adverse Events. Started May 2019; status: completed.
02
Drugs
difelikefalin
03
Conditions
uremic pruritus
Beyond the preview
Go deeper on NCT03998163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03998163.